Related Experiment Videos

Asthma severity, recommended changes of inhaled therapy and exhaled nitric oxide in children: a prospective, blinded

M Griese1, M Koch, P Latzin

  • 1Kinderpoliklinik and Kinderklinik, Dr. von Hauner Childrens' Hospital, Ludwig-Maximilians-University, Pettenkoferstr 8a, D-80336 Munich, Germany. griese@pk-i.med.uni-muenchen.de

European Journal of Medical Research
|August 26, 2000
PubMed

Insights

Orally exhaled nitric oxide (ENO) in children with allergic asthma showed a weak correlation with disease severity and therapy adjustments. Further studies are needed to determine if ENO can effectively guide asthma treatment.

Area of Science:

  • Pediatric Pulmonology
  • Allergy and Immunology
  • Biomarkers in Respiratory Disease

Background:

  • Airway inflammation is a key feature of asthma.
  • Orally exhaled nitric oxide (ENO) is a non-invasive marker of airway inflammation.
  • The utility of ENO in guiding asthma therapy requires further investigation.

Purpose of the Study:

  • To evaluate the correlation between ENO levels and asthma severity in children.
  • To assess the predictive value of ENO for therapeutic decisions in pediatric allergic asthma.
  • To determine if ENO can be used as a tool to direct asthma management.

Main Methods:

  • Seventy-four children with allergic asthma and 31 healthy controls were enrolled.
  • Asthma severity was assessed using medical history, clinical symptoms, and lung function.
  • ENO was measured, but results were blinded to patients, parents, and physicians during therapeutic decision-making.

Main Results:

  • ENO levels were significantly higher in asthmatic children compared to controls.
  • ENO did not significantly correlate with asthma severity.
  • ENO showed a weak correlation with recommended changes in inhaled therapy (r = 0.303, P = 0.009).
  • ENO values above 13 ppb demonstrated moderate sensitivity (0.67) and specificity (0.65) in predicting therapy escalation.

Conclusions:

  • ENO levels do not strongly correlate with asthma severity in children.
  • The predictive value of ENO for guiding asthma therapy adjustments is limited.
  • While ENO may offer some value, further research is essential to establish its role in directing pediatric asthma management.

Related Concept Videos

Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Asthma III: Clinical Manifestations01:13

Asthma III: Clinical Manifestations

Asthma presents with a characteristic pattern of episodic respiratory symptoms that reflect underlying airway inflammation, bronchoconstriction, and mucus hypersecretion. Although severity varies among individuals, certain clinical manifestations are considered hallmarks of the disorder and often guide diagnosis and assessment.Respiratory SymptomsA persistent cough is one of the most common early features of asthma. It is frequently dry and tends to worsen at night or in the early morning,...
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma-III: Symptoms and Complications01:24

Asthma-III: Symptoms and Complications

Asthma, a common chronic respiratory condition, is classified considering the frequency and severity of symptoms alongside lung function impairment. Understanding this classification is essential for appropriate treatment and management. Here's a detailed look at the classification of asthma and its clinical features and complications:
Classification of Asthma
Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include: